Skip to main content
enGene Holdings Inc. logo

enGene Holdings Inc. - Investor Relations & Filings

Listed IPO Nov 2023
Ticker · ENGN ISIN · CA29286M1059 LEI · 529900NE5JFN74BYXQ13 US Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2026-07-17 Regulatory Filings
Country CA Canada
Listing US ENGN

Key figures FY2025

Period ended 2025-10-31 · USD
Headline annual figures for enGene Holdings Inc., fiscal year 2025, reported in USD, with the source filing for each figure.
Net Income USD -117.30M per the Annual Report filed 2025-12-22
Total Assets USD 221.47M per the Annual Report filed 2025-12-22
Total Equity USD 167.71M per the Annual Report filed 2025-12-22
Cash from Ops USD -99.24M per the Annual Report filed 2025-12-22

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About enGene Holdings Inc.

https://engene.com/

enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral gene therapies. The company's proprietary platform is designed for the local delivery of DNA-based immunotherapies directly to mucosal tissues and other organs. Its lead product candidate, EG-70 (detalimogene voraplasmid), is an intravesical therapy being evaluated for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapeutic approach aims to stimulate a patient's own immune system to attack tumor cells. By avoiding viral vectors, enGene seeks to create re-dosable genetic medicines that can be administered without the complexities and potential immunogenicity associated with viral-based systems, with the goal of making gene-based treatments more accessible.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC. Form 8-K is a 'Current Report' used to announce major events that shareholders should know about. In this specific instance, the company is using the 8-K to furnish a 'Corporate Presentation' under Item 7.01 (Regulation FD Disclosure). Since the 8-K itself is a general regulatory filing used for various disclosures and does not fit into the specific categories of financial reports (like 10-K or IR) or specific event types (like M&A or DIRS), it falls under the RNS (Regulatory Filings) category as the designated fallback for miscellaneous regulatory announcements.
2026-07-17 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC. Item 5.02 explicitly details the resignation of a director and chairman of the Board, and the appointment of a new chairman. While Form 8-K is a general regulatory filing, the specific content regarding the departure and appointment of board members falls directly under the 'Board/Management Information' category.
2026-07-16 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, an amendment to a previously filed Current Report on Form 8-K. It discusses updates related to workforce reductions, stock-based compensation expense, performance-based equity awards, and appointment of compensatory arrangements for executive officers. There are no full financial statements or detailed financial analysis typically found in quarterly or annual reports. The report focuses on disclosures about restructuring costs, executive compensation via equity awards, and changes to management compensation arrangements. Such content fits the scope of Regulatory Filings (RNS), which are for miscellaneous regulatory disclosures that do not neatly fall into other specific categories defined.
2026-06-18 English
10-Q
Interim / Quarterly Report Q2 2026
2026-06-15 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2026, from enGene Therapeutics Inc. The text includes announcements of quarterly financial results, workforce reductions and restructuring plans, and multiple management changes including resignations and appointments of senior officers and directors. The main focus is on changes in senior management and board-related information, including resignations, new appointments, separations, and reappointments of key executives and officers. There is no comprehensive financial report data or detailed financial statements that would qualify as an Annual or Interim Report. Nor is this a transcript, capital update, or other specialized report type. The content clearly aligns with announcements related to changes in board and senior management. Therefore, the correct classification is Board/Management Information (MANG).
2026-06-15 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed under Item 5.07 detailing the results of shareholder votes at the 2026 Annual General Meeting, including vote counts for director elections and auditor appointment. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-06-10 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.